or Try an Advanced Search...

    Technical Analysis for PALI - Palisade Bio, Inc.

    Grade Last Price % Change Price Change
    F 4.30 -4.44% -0.20
    PALI closed down 4.44 percent on Monday, July 1, 2024, on 2 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Jul 8
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical PALI trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    Outside Day Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Older End-of-Day Signals for PALI ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 4 hours ago
    Fell Below Lower Bollinger Band about 4 hours ago
    Lower Bollinger Band Support about 4 hours ago
    Down 2 % about 5 hours ago
    Outside Day about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PALI Chart by TradingView
    Basic chart:

    Profile

    Palisade Bio, Inc. Description

    Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Surgery Abdominal Pain Gastrointestinal Tract Digestive System

    Is PALI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 Palisade Bio to Participate in the Virtual Investor Closing Bell Series
    Jun 21 Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
    Jun 11 Palisade Bio gets notice of allowance for Canadian patent covering lead product candidate
    Jun 11 Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
    Jun 10 Palisade Bio to Present at the Virtual Investor Pitch Conference
    May 21 Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
    May 14 Palisade Bio GAAP EPS of -$4.59
    May 14 Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
    May 7 Palisade Bio Appoints Margery Fischbein to its Board of Directors
    May 7 Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
    See more PALI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 36.6
    52 Week Low 3.82
    Average Volume 775,510
    200-Day Moving Average 7.14
    50-Day Moving Average 5.48
    20-Day Moving Average 4.58
    10-Day Moving Average 4.60
    Average True Range 0.37
    RSI (14) 35.90
    ADX 11.15
    +DI 21.58
    -DI 16.84
    Chandelier Exit (Long, 3 ATRs) 4.05
    Chandelier Exit (Short, 3 ATRs) 5.39
    Upper Bollinger Bands 4.82
    Lower Bollinger Band 4.34
    Percent B (%b) -0.09
    BandWidth 10.45
    MACD Line -0.24
    MACD Signal Line -0.27
    MACD Histogram 0.0312
    Fundamentals Value
    Market Cap 52.16 Million
    Num Shares 12.1 Million
    EPS 0.32
    Price-to-Earnings (P/E) Ratio 13.44
    Price-to-Sales 21.88
    Price-to-Book 0.39
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.93
    Resistance 3 (R3) 5.00 4.86 4.83
    Resistance 2 (R2) 4.86 4.70 4.83 4.79
    Resistance 1 (R1) 4.58 4.60 4.51 4.51 4.75
    Pivot Point 4.44 4.44 4.41 4.41 4.44
    Support 1 (S1) 4.16 4.28 4.09 4.09 3.85
    Support 2 (S2) 4.02 4.18 3.99 3.81
    Support 3 (S3) 3.74 4.02 3.78
    Support 4 (S4) 3.67